P533: Ustekinumab therapeutic drug monitoring in Crohn’s disease patients with loss of response
ECCO '19 Copenhagen
2019
P534: IBD-related malignancies observed in 2015–2018: 4 years’ results from the prospective nationwide Hungarian registry
ECCO '19 Copenhagen
2019
P536: Thiopurine metabolite levels in pregnant IBD patients and infants following intrauterine thiopurine exposure
ECCO '19 Copenhagen
2019
P537: The impact of early disease control with vedolizumab on surgery rates among patients with Crohn’s disease: a post-hoc analysis of the GEMINI trials
ECCO '19 Copenhagen
2019
P538: Vedolizumab is effective in real life paediatric inflammatory bowel disease: report from the prospective, multi-centre VEDOKIDS cohort study
ECCO '19 Copenhagen
2019
P539: Impact of a multi-disciplinary team meeting for managing inflammatory bowel disease patients: professional practice analysis based on 869 cases
ECCO '19 Copenhagen
2019
P540: Therapeutic drug monitoring in ustekinumab: which factors affect trough levels?
ECCO '19 Copenhagen
2019
P541: Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study
ECCO '19 Copenhagen
2019
P542: Efficacy and safety of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience
ECCO '19 Copenhagen
2019
P543: Seven-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
ECCO '19 Copenhagen
2019
P544: Impact of patient education on switch acceptance in IBD patients in remission, with infliximab originator switched for an infliximab biosimilar: a prospective study
ECCO '19 Copenhagen
2019
P545: Elderly patients with inflammatory bowel disease (IBD) are less likely to persist on anti-TNF therapy compared with younger patients: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
ECCO '19 Copenhagen
2019
P546: Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease
ECCO '19 Copenhagen
2019
P547: Distribution of mesenteric macrophage polarisation: a guide for surgical resections in Crohn’s disease?
ECCO '19 Copenhagen
2019
P548: Vedolizumab clinical decision support tool predicts hospitalisation, surgery, and healthcare resource utilisation
ECCO '19 Copenhagen
2019
P549: Vitamin D deficiency as a part of extraintestinal manifestations in IBD Patients: a single-centre experience
ECCO '19 Copenhagen
2019
P550: Anti-mycobacterium paratuberculous therapy in Crohn’s disease: outcomes from tertiary IBD referral centres
ECCO '19 Copenhagen
2019